[BIIB] Biogen Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 287.53 Change: 4.46 (1.58%)
Ext. hours: 292.98 Change: 5.45 (1.9%)

chart BIIB

Refresh chart

Strongest Trends Summary For BIIB

BIIB is in the long-term up 254% in 20 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn?s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company?s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical tri

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS17.73 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.19% Sales Growth - Q/Q1.44% P/E14.2
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA20.83% ROE27.76% ROI24.82%
Current Ratio2.2 Quick Ratio1.86 Long Term Debt/Equity0.19 Debt Ratio0.2
Gross Margin88.36% Operating Margin45.28% Net Profit Margin33.89% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities77.22 M Cash From Investing Activities-1.76 B Cash From Operating Activities1.78 B Gross Profit2.31 B
Net Profit927.28 M Operating Profit1.23 B Total Assets16.76 B Total Current Assets5.62 B
Total Current Liabilities2.56 B Total Debt579.47 M Total Liabilities4.19 B Total Revenue2.59 B
Technical Data
High 52 week383.83 Low 52 week219.29 Last close235.8 Last change-1.02%
RSI53.32 Average true range6.6 Beta1.03 Volume1.07 M
Simple moving average 20 days-0.53% Simple moving average 50 days0.76% Simple moving average 200 days-10.8%
Performance Data
Performance Week-2.67% Performance Month1.81% Performance Quart4.23% Performance Half-22.99%
Performance Year-27.62% Performance Year-to-date-30.73% Volatility daily1.64% Volatility weekly3.66%
Volatility monthly7.5% Volatility yearly25.97% Relative Volume178.46% Average Volume1.55 M
New High New Low


2019-09-20 16:43:52 | Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed

2019-09-20 11:04:03 | Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF PBE?

2019-09-19 11:30:03 | Biogen's New Study to Test Higher Dose of SMA Drug Spinraza

2019-09-19 07:17:11 | Alexion ALXN Down on News of CFO Clancy's Departure in 2019

2019-09-18 10:33:02 | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

2019-09-18 10:04:02 | Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis

2019-09-18 07:30:00 | Biogen Advances Spinal Muscular Atrophy SMA Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® nusinersen and Additional Data in a Broad Range of Patients

2019-09-17 16:05:36 | 6 Undervalued Companies Growing Earnings

2019-09-17 07:30:00 | Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

2019-09-16 11:49:38 | This Biotech Stock Just Rocketed 83% On A $2 Billion Takeover Deal

2019-09-16 11:30:00 | S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

2019-09-16 10:17:02 | The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors

2019-09-16 10:16:02 | Biogen Stops Late-Stage Studies on Alzheimer's Candidate

2019-09-14 06:31:25 | 3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

2019-09-13 16:18:23 | Biogen Scraps 2 More Studies In Alzheimer's Disease — And Shares Pop

2019-09-13 10:05:05 | Biogen, Eisai halt work on second of 3 clinical-stage Alzheimer's drugs

2019-09-13 08:44:42 | UPDATE 2-Biogen scraps two late-stage trials for Alzheimer's treatment

2019-09-13 08:42:12 | What September Doldrums? Here's Why Stocks Are Moving Higher

2019-09-13 08:18:00 | Biogen's stock falls after co. and Eisai to discontinue late-stage trial of Alzheimer's treatment

2019-09-13 08:00:00 | Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

2019-09-13 07:45:11 | Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate

2019-09-13 05:32:00 | Biogen Rises After Canceling Two Late-Stage Alzheimer's Trials

2019-09-12 15:15:41 | Does Biogen Inc.'s NASDAQ:BIIB CEO Pay Matter?

2019-09-12 05:00:00 | New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

2019-09-11 07:09:41 | The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway

2019-09-11 05:00:00 | New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® dimethyl fumarate Over 10 Years

2019-09-09 10:10:02 | Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group

2019-09-08 17:09:22 | Stocks That Fell to 3-Year Lows in the Week of Sept. 6

2019-09-05 17:01:23 | 6 Stocks With Low Price-Sales Ratios

2019-09-05 08:05:12 | 5 Price-to-Book Value Picks for September

2019-09-04 10:17:57 | Biotech vet George Scangos steers new company toward nine-figure IPO

2019-09-04 09:37:01 | Novartis Inks Commercialization Deal for Tysabri Biosimilar

2019-09-01 07:00:00 | Better Buy: Gilead Sciences vs. Biogen

2019-08-30 08:04:12 | Novartis' NVS MS Drug Achieves Goals in Late-Stage Studies

2019-08-28 14:15:06 | Ionis IONS Out-licenses Hepatitis B Virus Program to Glaxo

2019-08-28 08:51:12 | 5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market

2019-08-25 14:00:00 | Better Buy: Biogen vs. Celgene

2019-08-24 17:46:26 | Stocks That Fell to 3-Year Lows in the Week of Aug. 23

2019-08-21 07:10:18 | Could The Biogen Inc. NASDAQ:BIIB Ownership Structure Tell Us Something Useful?

2019-08-21 06:00:00 | Biogen- Buybacks and Biotech

2019-08-20 07:30:00 | Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy SMA to Improve Speed of Diagnosis for Patients

2019-08-19 08:04:12 | AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA

2019-08-14 09:35:01 | Amgen AMGN Soars to 52-Week High, Time to Cash Out?

2019-08-14 09:10:01 | Are Investors Undervaluing Biogen BIIB Right Now?

2019-08-13 10:43:02 | Mergers & Acquisitions Take Center Stage in Biotech Industry

2019-08-12 09:09:01 | Top Ranked Momentum Stocks to Buy for August 12th

2019-08-12 08:59:12 | 5 ROE Stocks to Profit as Trade War Spurs Volatility

2019-08-08 10:17:02 | PDL BioPharma PDLI Q2 Earnings Top Mark, Revenues Fall Y/Y

2019-08-08 09:26:01 | Intercept ICPT Q2 Earnings & Sales Beat, NASH in Focus

2019-08-07 19:54:45 | Sarepta moves beyond rare disease, eyes multiple sclerosis gene therapy